ARTICLE | Clinical News

Vemlidy regulatory update

November 11, 2016 8:30 PM UTC

FDA approved an NDA from Gilead for once-daily oral Vemlidy tenofovir alafenamide fumarate (TAF) to treat chronic HBV infection in patients with compensated liver disease. On Nov. 10, Gilead said Vemlidy would be available the following week at a price of $997.77 for a 30-tablet bottle, "at parity" with the price of Gilead's HBV therapy Viread tenofovir disoproxil fumarate (TDF)...

BCIQ Company Profiles

Gilead Sciences Inc.